— An experimental treatment, gantenerumab, failed to help people at high risk of memory loss from Alzheimer’s or those who were in the early phases of the disease, the manufacturer said Monday. Gantenerumab is part of a class of injected drugs that are designed to remove sticky protein pieces called beta amyloid from the brain. Beta amyloid buildup is a hallmark of Alzheimer’s disease. Gantenerumab is part of a class of injected drugs that are designed to remove sticky protein pieces called beta amyloid from the brain. Beta amyloid buildup is a hallmark of Alzheimer’s disease. Gantenerumab is part of a class of injected drugs that are designed to remove sticky protein pieces called beta amyloid from the brain. Beta amyloid buildup is a hallmark of Alzheimer’s disease. Gantenerumab is part of a class of injected drugs that are designed to remove sticky protein pieces called beta amyloid from the brain. Beta amyloid buildup is a hallmark of Alzheimer’s disease. Gantenerumab is part of a class of injected drugs that are designed to remove sticky protein pieces called beta amyloid from the brain. Beta amyloid buildup is a hallmark of Alzheimer’s disease. Gantenerumab is part of a class of injected drugs that are designed to remove sticky protein pieces called beta amyloid from the brain. Beta amyloid buildup is a hallmark of Alzheimer’s disease. Gantenerumab is part of a class of injected drugs that are designed to remove sticky protein pieces called beta amyloid from the brain. Beta amyloid buildup is a hallmark of Alzheimer’s disease. Gantenerumab is part of a class of injected drugs that are designed to remove sticky protein pieces called beta amyloid from the brain. Beta amyloid buildup is a hallmark of Alzheimer’s disease. Gantenerumab is part of a class of injected drugs that are designed to remove sticky protein pieces called beta amyloid from the brain. Beta amyloid buildup is a hallmark of Alzheimer’s disease. Gantenerumab is part of a class of injected drugs that are designed treatment — A new study has found evidence -An experiment on mice with an eye condition similar Alzheimer’s may be linked by researchers and scientists around world as they continue their search for treatments against this debilitating illness which affect millions worldwide every year. The study was published online today in the journal Nature Medicine. The research team led Dr Sanjai Gautam (pictured) says it could lead them towards developing